Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.92 |
| ▸ | IGF1R | P08069 | 5/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | IKBKB | O14920 | 1/20 | 0.68 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.68 |
| ▸ | PRKCG | P05129 | 1/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 1/20 | 0.68 |
| ▸ | PIM1 | P11309 | 1/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.68 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.68 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1377802 | 0.96 | EGFR (1.00) | EGFRIGF1RKDRAURKANPC1 | |
| SCHEMBL17915954 | 0.88 | EGFR (0.84) | EGFRIGF1RKDRNPC1MAPT | |
| SCHEMBL1116424 | 0.87 | EGFR (0.83) | EGFRIGF1RKDRAURKANPC1 | |
| SCHEMBL6976694 | 0.86 | EGFR (0.81) | EGFRIGF1RKDRCDK2ROCK1 | |
| SCHEMBL270162 | 0.84 | EGFR (0.78) | EGFRIGF1RKDRAURKANPC1 | |
| SCHEMBL301779 | 0.84 | EGFR (0.78) | EGFRIGF1RKDRNPC1MAPT | |
| SCHEMBL10143423 | 0.83 | EGFR (0.64) | EGFRIGF1RKDRNPC1MAPT | |
| SCHEMBL4544861 | 0.82 | KCNH3 (0.70) | EGFRKDRNPC1MAPTMAPK1 | |
| SCHEMBL4544834 | 0.82 | KCNH3 (0.70) | EGFRKDRNPC1MAPTMAPK1 | |
| SCHEMBL6971010 | 0.82 | EGFR (0.74) | EGFRIGF1RKDRCDK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | Viradem, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2024151953-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY SARS-COV-2 AND OTHER CORONAVIRUSES | VIRADEM INC. (US) | 2024-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076973-A1 | Compounds and methods for treating diseases caused by SARS-CoV-2 and other coronaviruses | ACE2, ACE, SARS1 | EGFR 471/4885IGF1R 4359/4885KDR 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.